Boundless Bio Inc (BOLD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.870.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BOLD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BOLD — M&A activity — Changes in Control of Registrant
Dated 2026-06-23
Changes in Control of Registrant. To the extent required by this Item, the information included in
Why it matters: Changes in cash runway guidance can show financial health and stability.
Watch forManagement says cash runway lasts until 2028 without changes.
Also watch forManagement revises cash runway guidance to less than 2028.
Why it matters: The job cuts are important for managing costs. They will show how the company adapts.
Worry ifBoundless Bio shows improved financial results after the cuts. This shows good cost control.
Less concerning ifOngoing losses or problems continue despite the job cuts.
Why it matters: Cutting jobs may hurt efficiency and morale. This can affect the company's strategy.
Worry ifManagement says job cuts have led to better efficiency or cost savings.
Less concerning ifReports show operational issues or low morale from the job cuts.
Why it matters: The merger will create a new company focused on AATD therapies. It may impact stockholder value.
Supportive ifThe merger is complete. The new company will trade as 'AATD'.
Worry ifThe merger fails to close due to stockholder or regulatory issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$134 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $367 loss on $10,000 · 3.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,046 loss on $10,000 · 30.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The merger is crucial for Boundless Bio's future as it transitions to Serapha Bio. This could impact operations and stockholder value.
Supportive ifThe merger closes successfully by the end of Q4 2026, meeting all closing conditions.
Worry ifThe merger does not close. This is due to unmet conditions or stockholder disapproval.
Why it matters: The dividend shows Boundless Bio's financial health. It shows their commitment to shareholders.
Supportive ifBoundless Bio plans to declare a cash dividend of about $44 to $48 million before the merger.
Worry ifNo cash dividend is announced, or the amount is much lower than expected.
Why it matters: This data is key to understanding the company's future and cash needs. If successful, it may attract more investment.
Supportive ifManagement will share early clinical data by the end of Q3 2026.
Worry ifNo clinical data will be shared by the end of Q3 2026.
Why it matters: This data is important for the BBI-940 program and the oncology strategy.
Supportive ifEarly data from the KOMODO-1 trial is released on time.
Worry ifData is late or shows no strong results. This raises concerns about the program.
Why it matters: Another earnings miss may show bigger problems. It could change how investors feel.
Worry ifQ2 earnings report shows a loss greater than the previous quarter's miss.
Less concerning ifQ2 earnings report shows a profit or a smaller loss than the previous quarter.
Why it matters: This data is key to extending the cash runway and shows progress in development. It could impact investor confidence.
Supportive ifManagement says they will share first clinical data results.
Worry ifNo clinical data results will be shared by the earnings call on August 4, 2026.